FIELD: physics.
SUBSTANCE: sample is irradiated with monochromatic X-ray radiation; the diffraction pattern from the sample is recorded in form of a profile of intensity of the diffraction X-ray radiation at different diffraction angles; diffraction peaks are selected; characteristics of the selected diffraction peaks are compared with similar characteristics of reference samples, from where phase composition of the analysed sample is determined; wherein for analysis, a series of samples is collected from each batch of the pharmaceutical product, said samples being in solid form and having packaging; each sample of the series with an intact structure is scanned without breaching the packaging; diffraction peaks corresponding to the packaging material are selected on the diffraction pattern; the range of angles for analysing the diffracted radiation is set, within which diffraction peaks for the material of each sample are selected, from which, using statistical methods, the identity of the corresponding series of samples, one of which is the reference, to one batch of the pharmaceutical product is established, and by selecting a standard series of the pharmaceutical product of a given manufacturer as the reference series, the authenticity of the pharmaceutical product is determined, wherein the wavelength of the monochromatic X-ray radiation is selected based on characteristics of the packaging material.
EFFECT: possibility of rapid analysis during investigation, identification and authentication of batches of pharmaceutical products in packaging.
10 cl, 12 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PERFORMING TABLETED MEDICINAL PREPARATIONS IN BLISTER PACKING BY NIR SPECTROMETRY | 2018 |
|
RU2685758C1 |
METHOD OF CAPSULAR DRUG PREPARATIONS TESTING IN BLISTER PACKAGE BY NIR SPECTROMETRY | 2018 |
|
RU2685756C1 |
CRYSTALLINE SOLID FORMS OF 6-CARBOXY-2-(3,5-DICHLOROPHENYL)BENZOXAZOLE | 2015 |
|
RU2692252C2 |
SOLID FORMS OF SELECTIVE CDK4/6 INHIBITOR | 2014 |
|
RU2619944C2 |
2-CHLORO-4-[1-(4-FLUOROPHENYL)-2,5-DIMETHYL-1H-IMIDAZOL-4-YLETHINYL]-PYRIDINE MONOSULPHATE SALT AND CRYSTALLINE FORM THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAID SALT AND PRODUCTION METHOD THEREOF | 2007 |
|
RU2460728C2 |
PHARMACEUTICAL COMPOSITION HAVING ANTIBIOTIC ACTIVITY | 2024 |
|
RU2822872C1 |
CRYSTALLINE FORMS OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA MALEATE | 2016 |
|
RU2717564C2 |
CRYSTALLINE FORMS GLYT1 | 2007 |
|
RU2463295C2 |
CRYSTALLINE FORMS OF KNOWN PYRROLIDINE INHIBITOR OF XA FACTOR | 2006 |
|
RU2368610C2 |
CRYSTALLINE FORM OF ASENAPINE MALEATE | 2006 |
|
RU2405786C2 |
Authors
Dates
2012-06-10—Published
2011-01-18—Filed